Improved Quality of Life With Ublituximab in the ULTIMATE I and II Studies in Relapsing Multiple Sclerosis By admin / 06/27/2022
Disability Improvements With Ublituximab in Relapsing Multiple Sclerosis: Pooled Post Hoc Analyses of the ULTIMATE I and II Studies By admin / 06/27/2022
Ublituximab Efficacy Outcomes in Relapsing Multiple Sclerosis Patient Subgroups in the ULTIMATE I and II Studies By admin / 06/26/2022
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis: Results of the Phase 3 ULTIMATE I and II Trials By admin / 06/18/2021
Open Label Extension (OLE) of Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS) By admin / 07/12/2019
